COMP <GO>
SRTA vs MRK // DIVIDEND YIELD & FCF PAYOUT SAFETY
Strata Critical Medical Inc. (Class A) (NASDAQ) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: SRTA 3
— MRK 9
▲ DIVIDEND YIELD & FCF PAYOUT SAFETY LEADER: MRK
LAST: $4.44 (-6.53%) • MKT CAP: $420.2M
dividend-safety
0.00%
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
dividend-safety
2.26%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SRTA VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SRTA | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 20.90% | 74.80% | -53.90 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -7.10% | 20.70% | -27.80 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -13.92% | 3.42% | -17.34 | MRK | /fcf-yield <GO> |
| Operating Margin | -11.30% | 34.30% | -45.60 | MRK | /operating-margins <GO> |
| Net Profit Margin | 21.00% | 28.10% | -7.10 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 34.30% | 1.30% | +33.00 | SRTA | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety ACTIVE | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.58 | 5.19 | +0.39 | SRTA | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 7/9 | -3.00 | MRK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 49.1 | 51.7 | -2.60 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 8.6x | 18.4x | -9.80 | SRTA | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $420.2M | $361.02B | -$360.60B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SRTA REV | MRK REV | SRTA GROSS % | MRK GROSS % | SRTA FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $197.1M | $65.01B | 20.9% | 74.8% | -$58.5M | $12.36B |
| FY 2024 | $146.8M | $64.17B | 20.2% | 76.3% | -$33.4M | $18.10B |
| FY 2023 | $225.2M | $60.12B | — | — | -$32.3M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SRTA // BETA —
MRK // BETA 0.92